Expert Interview
Discussing the recent Phase 2 data on Lipocene's LPCN 2401 in patients with obesity with a focus on body composition and muscle mass
Ticker(s): LPCNInstitution: WUSTL
- Associate Professor of Endocrinology, Metabolism & Lipid Research at Washington University in St. Louis
- Treats about 60 patients per month for T2D and obesity
- Clinical specialty in Thyroid disease, diabetes, pituitary disease, osteoporosis (brittle bones), parathyroid disease, high triglycerides, adrenal disease, high cholesterol, gonadal, low high-density lipoprotein cholesterol (HDL), and pancreatic islet disorders.
What are your thoughts on the mechanism of action in LPCN 2401?
Added By: sara_adminWhat are looking to see in terms of endpoints in a Phase 3 trial of LPCN 2401?
Added By: sara_adminIf you had to rate your level of excitement on a 1 to 10 scale for the potential of LPCN 2401, what would it be and why?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
